CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Polaryx Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Polaryx Therapeutics Inc
140 East Ridgewood Avenue
Suite #415, South Tower
Phone: (201) 940-7236p:201 940-7236 PARAMUS, NJ  07652  United States Ticker: PLYXPLYX
Business Summary
BRIEF: For the three months ended 30 September 2025, Polaryx Therapeutics Inc revenues was not reported. Net loss increased 85% to $1.4M. Higher net loss reflects Biotechnology &Medical reserch segment loss increase of 26% to $974K. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.02 to -$0.03.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer AlexYang 56 3/1/2023 6/1/2021
Chief Financial Officer, Director G. MichaelLandis 59 8/1/2025 6/1/2024
Chief Investment Officer AndrewO 53 1/1/2026 6/1/2022
4 additional Officers and Directors records available in full report.

General Information
Number of Employees: 2 (As of 11/1/2025)
Outstanding Shares: 47,343,297 (As of 9/30/2025)
Stock Exchange: NASD


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, February 27, 2026